Martin Stork

13PUBLICATIONS
61CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 12, 2026
Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

|Oct 11, 2024
Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry.

Ludmila Muronova, Ondrej Soucek, David Zihala

|Aug 26, 2024
Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed/refractory multiple myeloma patients: A retrospective analysis.

Dominik Fric, Martin Stork, Ivanna Boichuk

|Dec 11, 2022
Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma.

Monika Vlachová, Jana Gregorová, Petra Vychytilová-Faltejsková

|Oct 27, 2022
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.

Jiri Minarik, Jakub Radocha, Alexandra Jungova

|Oct 27, 2022
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas.

Martin Stork, Sabina Sevcikova, Tomas Jelinek

Pageof 3

Frequent Collaborators

7 joint publications

Sabina Sevcikova

7 joint publications

Jiri Minarik

5 joint publications

Roman Hajek

5 joint publications

Tomas Jelinek